INDICATIONS:

Talymed® is intended for use under the direction of a healthcare professional.

Talymed® is indicated for the management of wounds including:

Diabetic ulcers
Venous ulcers
Pressure wounds
Ulcers caused by mixed vascular etiologies
Full thickness and partial thickness wounds
Second degree burns
Surgical wounds-donor sites/grafts, post-Moh's surgery, post-laser surgery, and other bleeding surface wounds
Abrasions, lacerations
Traumatic wounds healing by secondary intention
Chronic vascular ulcers
Dehisced surgical wounds

#400-19/10x10
#400-20/5x5
#400-30/3x3

MPS 500-59 rev 06 10/2014

Talymed®

MPT MARINE POLYMER TECHNOLOGIES
Innovative Medical Solutions

Marine Polymer Technologies, Inc.
107 Water Street
Danvers, MA 01923
1-888-666-2560

Made in U.S.A.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician or other licensed practitioner.

DESCRIPTION: Talymed® is a sterile wound matrix comprised of shortened fibers of poly-N-acetyl glucosamine, isolated from microalgae.

PRECAUTIONS: There are no known contraindications to the use of Talymed®.

NOT MADE WITH NATURAL RUBBER LATEX
Sterilized with radiation.
ONE TIME USE ONLY
Do not resterilize and/or reuse.

The suggested application instructions are provided as a general guideline. Wound management protocols of care should be based on judgment of the professional healthcare practitioner through clinical assessment of the individual patient and institutional protocols.

Application Procedure

1. Treat and manage acute infection and debride any necrotic /devitalized tissue, if present, prior to initiation of Talymed®.
2. Gently cleanse wound bed with normal saline or sterile water.
3. Open Talymed® blister pack using sterile or aseptic technique based on care setting and facility protocol.
4. Use forceps or gloved hand to gently remove Talymed® from packaging and apply to wound bed.
5. Apply Talymed® in a dry state, positioning for maximum wound coverage. Trim, position, and conform additional Talymed® as needed to assure coverage of the entire wound surface and wound margin allowing for a slight peri-wound margin overlap to facilitate contact with the basement membrane zone.Talymed® will not harm intact skin. If additional Talymed® is required for full coverage of the wound and margin, slightly overlap edges of the matrix to assure no gaps are present.
6. Use drops of sterile water, saline, saline saturated gauze, or a moistened sterile swab to “pat” matrix in place and facilitate intimate contact, full matrix integration, and coverage of all aspects of wound bed and margin. Matrix will change from white to clear, signaling integration. Additional saline or sterile water may not be necessary, if wound is heavily draining or wound bed is very moist from cleansing and Talymed® conforms and integrates upon contact with the wound bed.
7. Cover Talymed® with a non-adherent, permeable primary dressing such as Mepitel® One or ADAPTIC® and may fixate with suture strips using a “window-pane” technique if desired.
8. Apply a secondary dressing of choice based on characteristics and level of drainage, assuring moisture balance and fluid handling capability. The secondary dressing may be changed or reinforced as needed. However, it is recommended to avoid disturbing Talymed® and the primary dressing for 5-7 days, or as clinical judgment determines.
9. Talymed® should be left in place and applied at a frequency based on clinical judgment or once weekly for optimal results. It is recommended that debridement, other than hyperkeratotic wound margins that could potentially compromise epithelial migration, should be avoided during the course of therapy to allow for scaffolding to build.
10. Employ adjunctive therapies such as compression, off-loading, and negative pressure wound therapy based on etiology, clinical judgment, and facility protocols.
11. When performing dressing changes, employ gentle wound cleansing techniques in cleansing the wound bed prior to reapplying Talymed®.
12. Reapply Talymed® by repeating previous application steps as required and continue until goal of therapy is achieved.
13. During the first 1-2 weeks of therapy with Talymed®, an increase in drainage may or may not be observed. During week 3-4 of therapy a caramelized appearance of the wound bed may or may not be noted. If a caramelized appearance is noted, do not attempt to remove if the wound exhibits positive signs of healing (i.e. diminishing wound size, epithelialization).